vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and KILROY REALTY CORP (KRC). Click either name above to swap in a different company.
ACADIA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($284.0M vs $272.2M, roughly 1.0× KILROY REALTY CORP). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs 6.3%, a 90.0% gap on every dollar of revenue. On growth, ACADIA PHARMACEUTICALS INC posted the faster year-over-year revenue change (9.4% vs -5.0%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs -1.2%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Kilroy Realty Corp is a leading U.S. real estate investment trust that develops, owns, and operates premium office, life science, and mixed-use properties primarily across high-growth West Coast markets including Los Angeles, San Francisco, Seattle, and San Diego. It serves tenants across the technology, life sciences, media, and creative sectors, with a core focus on delivering sustainable, future-ready workspaces tailored to modern business needs.
ACAD vs KRC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $272.2M |
| Net Profit | $273.6M | $17.1M |
| Gross Margin | 90.8% | — |
| Operating Margin | 6.1% | — |
| Net Margin | 96.3% | 6.3% |
| Revenue YoY | 9.4% | -5.0% |
| Net Profit YoY | 90.3% | -73.7% |
| EPS (diluted) | $1.61 | $0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $272.2M | ||
| Q3 25 | $278.6M | $279.7M | ||
| Q2 25 | $264.6M | $289.9M | ||
| Q1 25 | $244.3M | $270.8M | ||
| Q4 24 | $259.6M | $286.4M | ||
| Q3 24 | $250.4M | $289.9M | ||
| Q2 24 | $242.0M | $280.7M | ||
| Q1 24 | $205.8M | $278.6M |
| Q4 25 | $273.6M | $17.1M | ||
| Q3 25 | $71.8M | $162.3M | ||
| Q2 25 | $26.7M | $79.6M | ||
| Q1 25 | $19.0M | $43.7M | ||
| Q4 24 | $143.7M | $65.0M | ||
| Q3 24 | $32.8M | $57.7M | ||
| Q2 24 | $33.4M | $54.5M | ||
| Q1 24 | $16.6M | $55.7M |
| Q4 25 | 90.8% | — | ||
| Q3 25 | 92.2% | — | ||
| Q2 25 | 92.2% | — | ||
| Q1 25 | 91.7% | — | ||
| Q4 24 | 91.6% | — | ||
| Q3 24 | 92.5% | — | ||
| Q2 24 | 92.5% | — | ||
| Q1 24 | 88.8% | — |
| Q4 25 | 6.1% | — | ||
| Q3 25 | 12.8% | — | ||
| Q2 25 | 12.2% | — | ||
| Q1 25 | 7.9% | — | ||
| Q4 24 | 59.1% | — | ||
| Q3 24 | 12.6% | — | ||
| Q2 24 | 12.6% | — | ||
| Q1 24 | 7.4% | — |
| Q4 25 | 96.3% | 6.3% | ||
| Q3 25 | 25.8% | 58.0% | ||
| Q2 25 | 10.1% | 27.4% | ||
| Q1 25 | 7.8% | 16.1% | ||
| Q4 24 | 55.4% | 22.7% | ||
| Q3 24 | 13.1% | 19.9% | ||
| Q2 24 | 13.8% | 19.4% | ||
| Q1 24 | 8.0% | 20.0% |
| Q4 25 | $1.61 | $0.11 | ||
| Q3 25 | $0.42 | $1.31 | ||
| Q2 25 | $0.16 | $0.57 | ||
| Q1 25 | $0.11 | $0.33 | ||
| Q4 24 | $0.86 | $0.50 | ||
| Q3 24 | $0.20 | $0.44 | ||
| Q2 24 | $0.20 | $0.41 | ||
| Q1 24 | $0.10 | $0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $179.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $5.4B |
| Total Assets | $1.6B | $10.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | $179.3M | ||
| Q3 25 | $258.0M | $372.4M | ||
| Q2 25 | $253.6M | $193.1M | ||
| Q1 25 | $217.7M | $146.7M | ||
| Q4 24 | $319.6M | $165.7M | ||
| Q3 24 | $155.1M | $625.4M | ||
| Q2 24 | $177.1M | $835.9M | ||
| Q1 24 | $204.7M | $855.0M |
| Q4 25 | $1.2B | $5.4B | ||
| Q3 25 | $917.3M | $5.5B | ||
| Q2 25 | $822.4M | $5.4B | ||
| Q1 25 | $765.2M | $5.4B | ||
| Q4 24 | $732.8M | $5.4B | ||
| Q3 24 | $577.2M | $5.4B | ||
| Q2 24 | $516.7M | $5.4B | ||
| Q1 24 | $464.0M | $5.4B |
| Q4 25 | $1.6B | $10.9B | ||
| Q3 25 | $1.3B | $11.0B | ||
| Q2 25 | $1.2B | $10.9B | ||
| Q1 25 | $1.1B | $10.9B | ||
| Q4 24 | $1.2B | $10.9B | ||
| Q3 24 | $976.9M | $11.4B | ||
| Q2 24 | $914.1M | $11.5B | ||
| Q1 24 | $855.1M | $11.6B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $566.3M |
| Free Cash FlowOCF − Capex | — | $450.3M |
| FCF MarginFCF / Revenue | — | 165.4% |
| Capex IntensityCapex / Revenue | — | 42.6% |
| Cash ConversionOCF / Net Profit | -0.18× | 33.10× |
| TTM Free Cash FlowTrailing 4 quarters | — | $833.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $566.3M | ||
| Q3 25 | $74.3M | $176.6M | ||
| Q2 25 | $64.0M | $143.7M | ||
| Q1 25 | $20.3M | $136.9M | ||
| Q4 24 | $40.4M | $541.1M | ||
| Q3 24 | $63.2M | $176.3M | ||
| Q2 24 | $25.0M | $88.7M | ||
| Q1 24 | $29.1M | $167.9M |
| Q4 25 | — | $450.3M | ||
| Q3 25 | $73.9M | $148.7M | ||
| Q2 25 | — | $118.4M | ||
| Q1 25 | — | $115.6M | ||
| Q4 24 | — | $440.8M | ||
| Q3 24 | $63.2M | $147.2M | ||
| Q2 24 | — | $69.5M | ||
| Q1 24 | — | $151.9M |
| Q4 25 | — | 165.4% | ||
| Q3 25 | 26.5% | 53.1% | ||
| Q2 25 | — | 40.9% | ||
| Q1 25 | — | 42.7% | ||
| Q4 24 | — | 153.9% | ||
| Q3 24 | 25.2% | 50.8% | ||
| Q2 24 | — | 24.7% | ||
| Q1 24 | — | 54.5% |
| Q4 25 | — | 42.6% | ||
| Q3 25 | 0.1% | 10.0% | ||
| Q2 25 | — | 8.7% | ||
| Q1 25 | — | 7.9% | ||
| Q4 24 | — | 35.0% | ||
| Q3 24 | 0.0% | 10.1% | ||
| Q2 24 | — | 6.8% | ||
| Q1 24 | — | 5.7% |
| Q4 25 | -0.18× | 33.10× | ||
| Q3 25 | 1.03× | 1.09× | ||
| Q2 25 | 2.40× | 1.81× | ||
| Q1 25 | 1.07× | 3.13× | ||
| Q4 24 | 0.28× | 8.32× | ||
| Q3 24 | 1.93× | 3.06× | ||
| Q2 24 | 0.75× | 1.63× | ||
| Q1 24 | 1.76× | 3.01× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
KRC
Segment breakdown not available.
